Global Gaucher Disease Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- SKU ID : GIR-GIR1905290068 14199133
- |
- Publishing Date: 08-Jul-2019
- |
- Region: Global
- |
- No. of pages: 115
Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals.
Scope of the Report:
The technical barriers of Gaucher disease industry are existed apparently. The key technology and higher level products are in the hand of the global leading enterprise like Sanofi, Shire, Actelion Pharma, Pfizer, etc.
There are 5 FDA-approved drugs for type I Gaucher’s disease, Cerezyme (imiglucerase) in 1993, Cerdelga (eliglustat) in 2014, VPRIV (velaglucerase alfa) for 2010, Elelyso (taliglucerase alfa) for 2012, and Zavesca (miglustat) in 2003. One KFDA-approved drugs for type I Gaucher’s disease Abcertin® for 2012.
The special provisions for orphan drugs for Gaucher disease is the key driver for the growth of this market. A few companies and researchers are now developing drugs that are in the clinical stage of development. These drugs are expected to aid in the treatment of Gaucher disease and their effectiveness will in turn promote growth in this market in the next few years.
The worldwide market for Gaucher Disease is expected to grow at a CAGR of roughly 2.7% over the next five years, will reach 1906.6 million US$ in 2024, from 1672 million US$ in 2019, according to a new study.
This report focuses on the Gaucher Disease in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Sanofi
Shire
Actelion Pharma
Pfizer (Protalix)
ISU ABXIS
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Enzyme Replacement Therapy
Substrate Reduction Therapy
Market Segment by Applications, can be divided into
Non-neuronopathic Gaucher Disease
Neuronopathic Gaucher Disease
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gaucher Disease product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Gaucher Disease, with price, sales, revenue and global market share of Gaucher Disease in 2017 and 2018.
Chapter 3, the Gaucher Disease competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gaucher Disease breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Gaucher Disease market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Gaucher Disease sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Scope of the Report:
The technical barriers of Gaucher disease industry are existed apparently. The key technology and higher level products are in the hand of the global leading enterprise like Sanofi, Shire, Actelion Pharma, Pfizer, etc.
There are 5 FDA-approved drugs for type I Gaucher’s disease, Cerezyme (imiglucerase) in 1993, Cerdelga (eliglustat) in 2014, VPRIV (velaglucerase alfa) for 2010, Elelyso (taliglucerase alfa) for 2012, and Zavesca (miglustat) in 2003. One KFDA-approved drugs for type I Gaucher’s disease Abcertin® for 2012.
The special provisions for orphan drugs for Gaucher disease is the key driver for the growth of this market. A few companies and researchers are now developing drugs that are in the clinical stage of development. These drugs are expected to aid in the treatment of Gaucher disease and their effectiveness will in turn promote growth in this market in the next few years.
The worldwide market for Gaucher Disease is expected to grow at a CAGR of roughly 2.7% over the next five years, will reach 1906.6 million US$ in 2024, from 1672 million US$ in 2019, according to a new study.
This report focuses on the Gaucher Disease in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Sanofi
Shire
Actelion Pharma
Pfizer (Protalix)
ISU ABXIS
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Enzyme Replacement Therapy
Substrate Reduction Therapy
Market Segment by Applications, can be divided into
Non-neuronopathic Gaucher Disease
Neuronopathic Gaucher Disease
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Gaucher Disease product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Gaucher Disease, with price, sales, revenue and global market share of Gaucher Disease in 2017 and 2018.
Chapter 3, the Gaucher Disease competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Gaucher Disease breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Gaucher Disease market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Gaucher Disease sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
